
Izvēlieties etiķeti
redzama tieši uz flakonaTorasemid
Medication
- Sūtām no Vācijas
Pasūtījums
- DHL ar izsekošanu
- Diskrēts iepakojums
Īsumā
Torasemid skaitļos
Galvenie rādītāji no mūsu leksikona. Velciet punktu pa līkni, lai redzētu, cik daudz paliek pēc vienas devas, pēc aprēķina.
Pilns leksikona ierakstsHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~3.5 hours
Simplified model without an absorption phase, half-life from the TPD lexicon. The lexicon gives 3 to 4 hours, we calculate with the middle.
Half-life
about3to4hours
duration 6 to 8 hours
- Class
- Loop diureticNKCC2 inhibitor
- Use
- Oral1x daily in the morning
- Sizes
- 10 mg1 size in the shop
What studies show
All 5 sources in the lexiconTorsemide vs furosemide after discharge in heart failure (TRANSFORM-HF) (opens in a new tab)
Mentz et al., JAMA, 2023Torasemide in chronic heart failure - results of the TORIC study (opens in a new tab)
Cosín & Díez, European Journal of Heart Failure, 2002- Vargo et al., Clinical Pharmacology & Therapeutics, 1995
Produktam Torasemid vēl nav laboratorijas analīzes. Balsot par toPasūtiet testu, mēs apmaksājam pusiVisas laboratorijas analīzes
Zināšanas
Viss par Torasemid
Detalizēta informācija drīzumā.
Is torsemide approved?
Yes. ChEMBL lists torsemide with phase 4 as the highest phase and first approval in 1993. ClinicalTrials.gov lists 56 trials with torsemide, as of 26 October 2026.
What did TRANSFORM-HF show?
2,859 patients received torsemide or furosemide after a hospital stay for heart failure. 26.1 versus 26.2 percent died, without difference. Death or hospital stay within 12 months did not differ significantly either (47.3 versus 49.3 percent).
How does absorption differ from furosemide?
Torsemide has a bioavailability of about 80 percent in healthy people, furosemide 26 to 65 percent. In heart failure the peak level was reached after 1.1 instead of 2.4 hours. Absorption varied less.
Why did earlier trials see an advantage?
An open trial with 234 patients found fewer hospital stays for heart failure (17 versus 32 percent). The TORIC observation with 1,377 patients saw lower mortality (2.2 versus 4.5 percent) but was not randomised. The larger randomised trial did not confirm this.
What about potassium?
In TORIC 12.9 percent on torsemide had low potassium at the end, 17.9 percent on furosemide or other diuretics. The groups were not randomised.
Do liver and kidney matter?
Torsemide is mainly broken down in the liver, only about 20 percent appear unchanged in the urine. In liver disease clearance fell to about half. In kidney failure total clearance stayed largely the same according to the review.
Saistītie
Saistītie produkti
Telmisartan
Medikamenti · Sirds un asinsvadi Sirds un asinsvadi
2 izmēri
Laboratorijā pārbaudīts
Ivermectin
Medikamenti · Kuņģis un aknas Kuņģis un aknas
1 izmērs
Fenbendazol
Medikamenti · Kuņģis un aknas Kuņģis un aknas
1 izmērs
Prednisone
Medikamenti · Kuņģis un aknas Kuņģis un aknas
1 izmērs
Torasemid